GrayBug Presenting at the 40th Annual Meeting & Exposition of the Controlled Release Society
05/09/2013

Product overview delivered at popular “Soapbox Sessions”

Online PR News – 09-May-2013 – BALTIMORE, MD – GrayBug has been selected to present this summer at the Controlled Release Society’s 40th Annual Meeting & Exposition on Sunday, July 21, 2013, in Honolulu, Hawaii.

We will be reviewing our two platform technologies for long-term controlled drug delivery into the eye following injection as well as provide an overview of our pipeline for diseases that affect vision including age-related macular degeneration and glaucoma.

"We are pleased to have been chosen to give an overview of GrayBug's cutting edge technologies for ocular drug delivery at this year's annual meeting at the very popular Soapbox Sessions on Innovation Sunday," says Christy Wyskiel, COO of GrayBug. "We will be reviewing our two platform technologies for long-term controlled drug delivery into the eye following injection as well as provide an overview of our pipeline for diseases that affect vision, including age-related macular degeneration and glaucoma."

About the Soapbox Sessions:
The Soapbox Sessions are a well-attended and very interactive part of the Controlled Release Society’s “Innovation Sunday” program. These sessions attract large audiences from pharmaceutical and biotechnology companies, venture capitalists, and others who are interested in exploring recent innovations and tools.

About GrayBug
GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company’s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye. These technologies were co-developed by the lead founder of GrayBug, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at Johns Hopkins University with joint appointments in four other Hopkins departments including Biomedical Engineering, in collaboration with top ophthalmology clinician-scientists from the Wilmer Eye Institute, Dr. Peter Campochiaro and Dr. Peter J. McDonnell. For more information, please visit www.graybug.com.

visit our website